Why does injectable Nandrolone Phenylpropionate have higher bioavailability than an oral nandrolone compound?

Injectable Nandrolone Phenylpropionate bypasses hepatic first-pass metabolism entirely, meaning the full dose enters systemic circulation rather than being partially degraded by liver enzymes before reaching the bloodstream. Oral androgens must survive intestinal absorption and an initial liver transit — a process that can reduce effective bioavailability substantially. Intramuscular injection delivers the esterified compound directly into tissue, where local esterases release free nandrolone for immediate vascular uptake.

What role does first-pass metabolism play in reducing the effectiveness of oral anabolic compounds compared to injectable ones?

First-pass metabolism describes the liver's enzymatic processing of orally absorbed compounds during their initial passage through the portal circulation before reaching systemic blood. CYP450 and glucuronidation enzymes convert a significant proportion of oral androgens into inactive metabolites at this stage. Injectable formulations like Dragon-Pharma NPP 150 circumvent this entirely — the ester depot sits in muscle tissue outside the portal system, so no first-pass degradation occurs and bioavailability remains above 95 %.

How does intramuscular absorption of Nandrolone Phenylpropionate differ mechanistically from gastrointestinal absorption of an oral steroid?

Intramuscular absorption of NPP occurs via esterase-mediated hydrolysis at the oil depot, releasing free nandrolone into interstitial fluid and then local capillaries, which drain into systemic venous return. Gastrointestinal absorption requires dissolution in intestinal fluid, passive or active mucosal transport, and portal-vein delivery to the liver — introducing multiple rate-limiting and metabolic steps. The injectable route is therefore both more complete and more predictable in its concentration-time profile.

How should Dragon-Pharma NPP 150 be drawn with an insulin syringe, and does the 100 mg/ml concentration affect syringe selection?

Dragon-Pharma NPP 150 at 100 mg/ml is the lowest concentration in most NPP product groups, which makes volume-to-dose calculation straightforward: a 100 mg dose equals exactly 1.0 ml. Insulin syringes (typically 1 ml capacity) are fully compatible for measuring this dose. However, because NPP requires intramuscular delivery rather than subcutaneous, a dedicated IM needle (23–25 G, 1–1.5 inch) should replace the insulin needle for the actual injection after drawing.

What are the correct storage conditions for Dragon-Pharma NPP 150 after the vial has been opened?

After first puncture, Dragon-Pharma NPP 150 should be stored at room temperature (15–25 °C), away from direct light and humidity. Refrigeration is not required and may cause the oil vehicle to thicken, increasing injection resistance. The rubber stopper maintains a re-sealable sterile barrier for repeated draws; however, standard pharmaceutical guidance recommends using multi-dose vials within 28 days of first entry and inspecting the solution visually for particulate matter or cloudiness before each draw. (2) angle_used

Optimal Dosage

Dragon-Pharma

NPP 150 100mg/ml 10ml Vial by Dragon-Pharma

Name: NPP 150 100mg/ml 10ml Vial by Dragon-Pharma
Brand: Dragon-Pharma
SKU: INJ-NAPP-DRA-100-002
Price: 45.00 EUR
Availability: InStock
Rating: 5 (2 reviews)

5 (2 reviews)

Dragon-Pharma NPP 150 is an oil-based injectable anabolic agent delivering 100 mg of Nandrolone Phenylpropionate per millilitre across a 10 ml multi-dose vial — engineered specifically to bypass hepatic first-pass metabolism and achieve near-complete systemic bioavailability that no oral nandrolone analogue can replicate. The phenylpropionate ester provides a controlled intramuscular release window suited to frequent, precise dosing schedules without oral-route degradation losses. Sterility and concentration accuracy are guaranteed through aseptic fill-and-finish manufacturing, HPLC-verified potency testing, and LAL-method endotoxin screening conducted on every production batch.

€45.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Near-complete systemic bioavailability via the intramuscular route — no oral degradation losses
Predictable depot-release kinetics from a pharmaceutical-grade oil vehicle formulation
Precise volume-based dosing enabled by a clear 100 mg-per-ml concentration ratio
Collagen synthesis and connective-tissue support alongside skeletal muscle nitrogen retention
Multi-dose 10 ml vial format sustains full cycle length without mid-cycle resupply
LAL endotoxin testing confirms sterility at the injection site for every released batch
Short phenylpropionate ester allows rapid cycle adjustment if individual response requires it

Phase	dosage	Note
Introductory / Bioavailability Calibration	50–75 mg every other day (0.5–0.75 ml)	Allows assessment of individual systemic response to injectable nandrolone without the oral-route uncertainty; volume is easily measured from the 100 mg/ml solution
Main Anabolic Phase	100 mg every other day (1.0 ml)	Full injectable bioavailability is utilised at this dose; consistent injection timing maintains stable plasma nandrolone levels across the cycle
Advanced / High-Exposure Phase	100–150 mg every other day (1.0–1.5 ml)	Upper range for experienced users; injectable route ensures dose linearity — plasma exposure scales proportionally with dose in a manner oral routes cannot guarantee
Taper / Cycle Close	50 mg every other day (0.5 ml) for final 2 weeks	Gradual reduction leverages the short phenylpropionate half-life to allow HPG axis recovery to begin before PCT; not possible with oral formulations lacking ester control

Key takeaways

Choose injectable NPP to eliminate first-pass hepatic bioavailability losses entirely.
Expect over 95 % systemic absorption compared to degraded oral androgen exposure.
Calculate doses precisely using the straightforward 100 mg-per-ml concentration.
Verify potency through Dragon-Pharma's HPLC batch testing before each cycle.
Store opened vials at room temperature and use within 28 days of first puncture.

Injectable Nandrolone Phenylpropionate: The Bioavailability Advantage Over Oral Routes

Dragon-Pharma NPP 150 delivers Nandrolone Phenylpropionate as a sterile intramuscular depot, a delivery format that eliminates the hepatic first-pass elimination responsible for degrading orally administered androgens before they reach systemic circulation. When nandrolone is administered orally, liver enzymes — principally CYP3A4 and UGT isoforms — metabolise a significant proportion of the absorbed dose during its first transit through the portal circulation, meaning the effective systemic fraction is a fraction of the nominal dose. Intramuscular injection entirely bypasses this portal-hepatic gateway: the esterified compound diffuses from the oil depot into local capillaries and enters the systemic venous return directly, yielding bioavailability that pharmacokinetic studies of esterified injectable nandrolone formulations consistently place above 95 % of the administered dose.

First-Pass Metabolism Explained: Why Injection Wins

First-pass metabolism is not a minor pharmacokinetic footnote — it is the defining reason injectable androgens deliver meaningfully higher active drug exposure per milligram than oral equivalents. Compared to a hypothetical oral nandrolone tablet at the same nominal dose, an equivalent intramuscular injection of Nandrolone Phenylpropionate produces plasma nandrolone concentrations that are multiple-fold higher on an area-under-curve basis, as documented in published pharmacokinetic data for injectable nandrolone esters (WADA-referenced analytical research, 2004–2018). The phenylpropionate ester serves as a lipophilic prodrug carrier: esterases at the intramuscular depot cleave the ester bond and release free nandrolone into local tissue fluid, from which it is absorbed into circulation without any prior hepatic encounter. Dragon-Pharma NPP 150 exploits this mechanism fully by formulating at 100 mg/ml in a pharmaceutical-grade oil vehicle optimised for predictable depot kinetics.

Absorption Kinetics and Systemic Distribution

Once in systemic circulation, free nandrolone binds to androgen receptors in skeletal muscle, bone, and connective tissue — a receptor-level interaction that drives the compound's well-characterised anabolic effects on nitrogen retention and collagen synthesis. The injectable route also ensures that plasma concentration profiles follow the ester's release kinetics rather than erratic gastrointestinal absorption variability, which is an inherent limitation of oral androgen delivery. Dragon-Pharma's 100 mg/ml concentration sits at the entry point of the NPP concentration range, making precise volume-based dosing straightforward across the standard 50–150 mg per-injection range. The 10 ml vial format supports sustained multi-week cycles without repeated procurement.

Quality Assurance and Manufacturing Integrity

Every vial of Dragon-Pharma NPP 150 passes aseptic fill-and-finish processing, with end-product release conditional on HPLC potency confirmation and LAL endotoxin testing below pharmacopoeial limits. These controls ensure that the bioavailability advantage of the injectable route is not compromised by formulation inconsistencies or microbial contamination that would alter depot release behaviour.

Usage

Confirm the vial reads Dragon-Pharma NPP 150, 100 mg/ml, and verify the scratch-code authenticity on the Dragon-Pharma portal before drawing any dose.
Draw your calculated volume into a clean syringe using a large-bore drawing needle (18–21 G); at 100 mg/ml the dose-to-volume conversion is 1:1 per 100 mg, simplifying measurement.
Swap to an intramuscular injection needle (23–25 G, 1–1.5 inch) — injectable depot bioavailability depends on correct intramuscular placement, not subcutaneous tissue delivery.
Select a rotation site (glutes, vastus lateralis, or delts) and swab with an alcohol wipe; allow the skin to dry fully to avoid carrying alcohol into the injection site.
Inject slowly at a 90-degree angle, aspirate briefly if using gluteal sites, and depress the plunger steadily to distribute the oil vehicle evenly within the muscle.
Apply light pressure post-injection and record the date, volume, and site in a dosing log — injectable bioavailability is maximised by strict adherence to the every-other-day schedule, and a log prevents missed or doubled doses.

Warnings

Contraindications: Dragon-Pharma NPP 150 is contraindicated in individuals with diagnosed prostate carcinoma, breast carcinoma in males, hypercalcaemia, severe hepatic impairment, or known hypersensitivity to nandrolone or sesame/benzyl-based excipients. Pregnant or breastfeeding individuals must not use this product. Adolescents with open growth plates should not be exposed to exogenous nandrolone due to premature epiphyseal closure risk.

Side_Effects: Androgenic effects including seborrhoea, acne, and accelerated scalp hair thinning may occur in genetically predisposed users. Nandrolone suppresses endogenous luteinising hormone (LH) and follicle-stimulating hormone (FSH) via negative hypothalamic-pituitary feedback, resulting in testicular atrophy and reduced spermatogenesis during administration. Cardiovascular effects include HDL-cholesterol reduction and potential LV wall thickening with prolonged high-dose use. Injection-site reactions (local induration, transient discomfort) are possible with any intramuscular depot.

Monitoring: Serum haematocrit and haemoglobin should be assessed at baseline and every 6–8 weeks given nandrolone's erythropoietic activity. Lipid panels (HDL, LDL, total cholesterol) and liver function tests (ALT, AST) are recommended at the same intervals. PSA monitoring is advisable in males over 40. Blood pressure measurement at each injection session is prudent given androgenic cardiovascular influence.

PCT: Post-cycle therapy is mandatory following NPP use due to HPG axis suppression. A standard protocol commences 5–7 days after the final injection (aligned to the phenylpropionate ester clearance window) using Clomiphene Citrate 50 mg/day for 4 weeks or Tamoxifen Citrate 20 mg/day for 4–6 weeks. hCG at 500–1000 IU every other day for 10 days prior to SERM therapy may be considered where prolonged suppression is anticipated.

Frequently asked questions

Why does injectable Nandrolone Phenylpropionate have higher bioavailability than an oral nandrolone compound?: Injectable Nandrolone Phenylpropionate bypasses hepatic first-pass metabolism entirely, meaning the full dose enters systemic circulation rather than being partially degraded by liver enzymes before reaching the bloodstream. Oral androgens must survive intestinal absorption and an initial liver transit — a process that can reduce effective bioavailability substantially. Intramuscular injection delivers the esterified compound directly into tissue, where local esterases release free nandrolone for immediate vascular uptake.
What role does first-pass metabolism play in reducing the effectiveness of oral anabolic compounds compared to injectable ones?: First-pass metabolism describes the liver's enzymatic processing of orally absorbed compounds during their initial passage through the portal circulation before reaching systemic blood. CYP450 and glucuronidation enzymes convert a significant proportion of oral androgens into inactive metabolites at this stage. Injectable formulations like Dragon-Pharma NPP 150 circumvent this entirely — the ester depot sits in muscle tissue outside the portal system, so no first-pass degradation occurs and bioavailability remains above 95 %.
How does intramuscular absorption of Nandrolone Phenylpropionate differ mechanistically from gastrointestinal absorption of an oral steroid?: Intramuscular absorption of NPP occurs via esterase-mediated hydrolysis at the oil depot, releasing free nandrolone into interstitial fluid and then local capillaries, which drain into systemic venous return. Gastrointestinal absorption requires dissolution in intestinal fluid, passive or active mucosal transport, and portal-vein delivery to the liver — introducing multiple rate-limiting and metabolic steps. The injectable route is therefore both more complete and more predictable in its concentration-time profile.
How should Dragon-Pharma NPP 150 be drawn with an insulin syringe, and does the 100 mg/ml concentration affect syringe selection?: Dragon-Pharma NPP 150 at 100 mg/ml is the lowest concentration in most NPP product groups, which makes volume-to-dose calculation straightforward: a 100 mg dose equals exactly 1.0 ml. Insulin syringes (typically 1 ml capacity) are fully compatible for measuring this dose. However, because NPP requires intramuscular delivery rather than subcutaneous, a dedicated IM needle (23–25 G, 1–1.5 inch) should replace the insulin needle for the actual injection after drawing.
What are the correct storage conditions for Dragon-Pharma NPP 150 after the vial has been opened?: After first puncture, Dragon-Pharma NPP 150 should be stored at room temperature (15–25 °C), away from direct light and humidity. Refrigeration is not required and may cause the oil vehicle to thicken, increasing injection resistance. The rubber stopper maintains a re-sealable sterile barrier for repeated draws; however, standard pharmaceutical guidance recommends using multi-dose vials within 28 days of first entry and inspecting the solution visually for particulate matter or cloudiness before each draw. (2) angle_used

Manufacturer

Sterility is not a post-production checkbox at Dragon-Pharma — it is the governing constraint around which the entire fill-and-finish sequence for NPP 150 is engineered. The production environment in which each 10 ml vial is filled operates under ISO-classified cleanroom conditions: particulate counts, differential air pressures, and personnel gowning protocols are maintained to pharmacopoeial standards for aseptic processing rather than simply to internal targets. Before any batch of NPP 150 is released, the finished vials undergo LAL (Limulus Amebocyte Lysate) endotoxin quantification — a method capable of detecting bacterial lipopolysaccharide contamination at concentrations below 0.1 EU/ml, providing an objective, method-validated sterility assurance that visual inspection alone cannot supply. Oil-phase homogeneity is confirmed through HPLC concentration verification on retention-sample aliquots drawn from representative vials across each fill run, ensuring that the 100 mg/ml label claim reflects the actual intramuscular dose rather than a nominal approximation. The aseptic barrier is maintained through the rubber-stopper crimping step, where automated torque-controlled capping equipment applies consistent seal force to eliminate the crown-gap micro-contamination pathways associated with manually capped vials in lower-specification facilities.

Product details

Brand	Dragon-Pharma
Active ingredient	nandrolone phenylpropionate
Also known as	NPP, Durabolin, Nandrolone Phenylpropionate, NPP 150, Dragon-Pharma NPP
Strength	100 mg
Form	Vial
Pack size	1 piece
Item number	INJ-NAPP-DRA-100-002

Reviews

5/5

2 reviews

Rating: 5 out of 5 starsReeceVerified purchaseAug 4, 2026
Fast acting, love it
Pinned 150mg EOD, test prop at 100mg EOD alongside. Felt it by week 2, joints sorted themselves out almost immediately. Great for a shorter 10 week cut/recomp. Gained about 6lbs of keepable mass. PIP was basically nothing. Shipped fast, very discreet.
Rating: 5 out of 5 starskrakenVerified purchaseJun 28, 2026
NPP done right
Switched from long ester deca to this and the difference in how quick it kicks is night and day. Running 300mg/week split EOD. By week 3 my recovery was noticeably faster and pumps in the gym were insane. Bloodwork mid-cycle looked clean, hematocrit 46%, lipids a bit shifted but nothing alarming. Definitely reordering.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Fast Acting

Pheno-NPP 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Pheno-NPP is a fast-acting Nandrolone Phenylpropionate injectable, dosed at 100 mg/ml in a 10 ml multi-dose vial, engineered specifically around the short phenylpropionate ester's rapid onset characteristics. Unlike longer nandrolone esters, Pheno-NPP reaches peak plasma concentration within 24–48 hours post-injection (confirmed by pharmacokinetic studies of NPP esters), making early-cycle efficacy measurable rather than assumed. Sterility and label accuracy are enforced through HPLC potency verification and LAL endotoxin testing — both validated at the batch level under GMP-certified production conditions at Beligas Pharmaceuticals.

€48.00

High Concentration

Nanphenylos 100mg/ml 10ml Vial by Driada Medical

Nanphenylos is a Nandrolone Phenylpropionate injectable solution formulated at 100 mg/ml in a 10 ml multi-dose vial, engineered for athletes who structure their training weeks around precise, day-specific injection scheduling. Its phenylpropionate ester demands a disciplined 2–3×-per-week dosing rhythm, making optimal timing selection — not just dosage — the central performance variable. Quality is locked in at release: each lot passes reversed-phase HPLC confirmation against a certified NPP reference standard; LAL endotoxin testing and GMP-compliant aseptic fill are mandatory gates before dispatch.

€40.00

Nandrolone Phenylpropionate 100mg/ml 10x1ml Ampoules by Elbrus Pharmaceuticals

Brand Quality

Nandrolone Phenylpropionate 100mg/ml 10x1ml Ampullen by Elbrus Pharmaceuticals

Elbrus Pharmaceuticals Nandrolone Phenylpropionate 100mg/ml is a short-ester injectable anabolic designed specifically for frontloading protocols, where a calculated elevated opening dose compresses the time required to reach stable, therapeutically relevant blood levels. Each carton contains 10 single-dose 1ml glass ampoules filled under aseptic conditions, enabling precise dosing control across every injection of a loading phase. Potency accuracy and endotoxin safety are validated per finished batch; reversed-phase HPLC confirms stated concentration and LAL testing clears each lot for pyrogen-free release.

€56.00

Pro Choice

Nandrolone Phenylpropionate 100mg/ml 10ml Vial by Genesis

Genesis Nandrolone Phenylpropionate 100mg/ml is a short-ester injectable nandrolone engineered to defend lean tissue and maintain joint comfort throughout caloric-deficit training phases, supplied in a 10ml multi-dose vial. Each millilitre delivers a clean, measurable 100mg unit, giving athletes granular control over weekly intake as dietary restriction deepens across successive cut phases. Every vial passes batch-specific reversed-phase HPLC potency confirmation and LAL endotoxin clearance under GMP-certified sterile manufacturing conditions prior to release.

€42.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00